SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Britain Courts Anthropic Amid US Defense Department Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will be presenting at the Stifel Healthcare Conference on November 16, 2016, at 8:00 a.m. Eastern Time. A live audio webcast of the presentation will be available in the “Investors” section of Threshold’s website, www.thresholdpharm.com. A replay of the presentation will be archived for 30 days following the conference.
About Threshold Pharmaceuticals
Threshold is a clinical-stage biopharmaceutical company focused on the development of drugs and diagnostic agents targeting the tumor microenvironment of solid tumors and hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit the Company’s website.
Contact: Denise Powell [email protected] 510.703.9491
